Aji Bio-Pharma Receives 2024 Best ADC Preclinical Publication Award

Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, announced it has been named the winner of the "Best ADC Preclinical Publication 2024" at the 12^th Annual World ADC Awards, recognizing the company's innovative research publication on the AJICAP^® linker technology.

"We are truly honored to receive this recognition from the World ADC community," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. "Our AJICAP^® technology reflects our dedication to empowering partners to bring innovative ADC therapies to the patients we collectively serve."

The World ADC Awards, organized by Hanson Wade, celebrate scientific and operational excellence across ADC discovery, development, and manufacturing. Aji Bio-Pharma was shortlisted for AJICAP^® in the "Best ADC Platform Technology" category and was further honored with winning the publication distinction. Winners are selected by an independent panel of ADC experts and peers representing the global biopharmaceutical community.

This recognition reflects Aji Bio-Pharma's continued commitment to driving innovation in ADC technology and supporting partners worldwide through the development and manufacturing of safer, more effective therapies.